The International Pharmaceutical Aerosol Consortium
Who We Are
In 1989, IPAC was formed in response to the mandate of the Montreal Protocol. The mandate was designed to combat substances that deplete the ozone layer and address the contribution of inhalation products to climate change.
The consortium strives to ensure global environmental policies that are relevant to inhaled therapies, are both patient-centric and appropriately balance patient care and sustainability efforts and objectives.
What We Do
IPAC is a consortium at the forefront of inhaled products and environmental policy issues. The coalition is comprised of AstraZeneca, Boehringer Ingleheim, Chiesi Farmaceutici, GSK, Kindeva, Organon, Cipla and Teva.
IPAC engages in policy issues around the world. The group actively engages in international dialogues with subteams working in the United Kingdom, European Union, United States, and internationally.
News & Events
May-September 2023
May - September 2023
IPAC, along with its sister organization IPAC-RS, submitted responses to the ECHA REACH proposal on PFAS. The organizations submitted a preliminary response in May 2023 and a second and final response in September 2023. Links to the submissions can be found on the Resource Hub page.
January 2023
IPAC joined with several health community stakeholders calling on policymakers to ensure access to critical medicines, including MDIs, while achieving important climate goals with a revised EU Fluorinated Greenhouse Gases Regulation.
IPAC Presents at RDD 2022
May 2022
Maureen Hardwick from the IPAC Secretariat presented at the Respiratory Drug Delivery (RDD) 2022 Conference in Orlando, Florida. The presentation was part of the Project Green MDI Segment and highlighted updates on the legislative process for the phase-out of hydrofluorocarbons. RDD brought together industry leaders to share key progress in the field of respiratory drugs.
April 2022
IPAC commends the European Commission on ambitious climate action with its proposal for revising the EU F-Gas Regulation. We believe it is imperative to maximize benefits to both patients and the climate. Please see IPAC’s statement here. We will be sharing additional perspectives on the implications for the regulation to patient care and the MDI sector shortly.
20-22 September 2021
Dr. Andy Rignall, IPAC's Chair presented on the regulatory landscape for inhaled therapies at APTAR's Sustainable pMDI Forum which brought together industry leaders and experts to discuss key developments regarding inhalers and the environment throughout the supply chain.